Overview of Section 1115 Medicaid Waivers: Current Status by State
This editorial provides an overview of the status of Section 1115 Medicaid waivers across various states, focusing on both approved and pending provisions.
Latest Health stories from Life.
This editorial provides an overview of the status of Section 1115 Medicaid waivers across various states, focusing on both approved and pending provisions.
On April 21, 2026, Robert F. Kennedy Jr. will participate in Senate hearings alongside four Republican doctors, with a focus on his interactions with Bill Cassidy.
In a recent opinion piece, Lawrence K. Altman argues that efforts to invoke the 25th Amendment for Trump's removal are misguided, providing insights into the complexities involved.
A judge is anticipated to impose a $225 million forfeiture on Purdue Pharma, the maker of OxyContin, facilitating the completion of its settlement with the Justice Department.
The biotech sector sees notable developments as Kelonia Therapeutics rebounds significantly, while BioAge focuses on inflammation and other industry updates emerge.
A U.S. judge is anticipated to order Purdue Pharma to forfeit $225 million, marking a significant step in ongoing legal proceedings.
Recent developments indicate that a CDC conference, previously open to the public, may now have restricted access. This follows a federal ruling related to gender declaration and highlights ongoing issues in health policy.
BioAge Labs has announced encouraging findings from an early study of its investigational pill designed to reduce cardiovascular risks by targeting inflammation.
Tortugas Neuroscience has officially launched, aiming to develop new treatments for brain disorders by leveraging licenses from Jiangsu Hansoh and Eisai.
KFF is set to debut a podcast hosted by Chip Kahn, focusing on the intricate relationship between health policy and business. The initiative aims to deepen understanding of these complexities.
The current U.S. health care system appears to prioritize retrospective evaluations, questioning the justification of past medical decisions.
The presence of executive dysfunction in a CEO can lead to considerable challenges for an organization, raising questions about leadership effectiveness.
This analysis explores the Executive Actions from the Trump administration that may affect the health of LGBTQ+ individuals, detailing their potential implications.
The recent AACR conference highlighted a daring application of CAR-T therapy, sparking discussions about its potential in treating smoldering multiple myeloma.
Andrew Baum, who previously served as Pfizer's executive vice president and chief strategy and innovation officer, has stepped down from his position.
Recent findings from a CAR-T trial suggest potential in preventing smoldering multiple myeloma from progressing to active disease in high-risk individuals.
While President Trump's executive order to advance psychedelic treatments has garnered enthusiasm from advocates, it also raises concerns about potential politicization and credibility issues.
Dimitri Mugianis and Ross Ellenhorn argue that while Republicans are increasingly supporting psychedelics, the essence of recovery transcends mere medication.
Despite health insurance accounting for 8% of total employee compensation, lower-wage workers continue to face significant challenges in accessing coverage.
The acquisition of Kelonia Therapeutics by Eli Lilly for $3.25 billion marks a significant turn for the struggling biotech firm, which faced numerous challenges.